COPD, FDA
China Approves World's First Targeted COPD Drug
The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised levels of eosinophil white blood cells, French pharmaceutical giant Sanofi, the drug’s developer, announced on Sept. 27.
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
FDA Approves Dupixent for Patients with COPD
After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD). Dupixent is the first biologic approved in the United States to treat these patients.
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
GlobalData on MSN2d
FDA greenlights Regeneron’s Dupixent for the treatment of COPDWith an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately ...
Investor's Business Daily on MSN2d
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For DupixentRegeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback